{
"select * from (\n\nSELECT DISTINCT 'Data Readouts' as key_events_label, a.rec_count, coalesce(ipp_short_name, '') as ipp_short_name, project_type, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\nFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \nINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \ncross join (select count() as rec_count  from (SELECT DISTINCT 'Data Readouts' as key_events_label, coalesce(ipp_short_name, '') as ipp_short_name, project_type, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\n\tFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \n\tINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \n\tWHERE activity_type in ('PRI_AN_FLASH', 'FLASH_MEMO') \n\tAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\n\tAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab)  between now() AND  date_add('month', 3, now()))) as a\nWHERE activity_type in ('PRI_AN_FLASH', 'FLASH_MEMO') \nAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\nAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, now())\n\nunion \n\nSELECT DISTINCT 'Filings' as key_events_label,a.rec_count, coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\nFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \nINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \ncross join (select count() as rec_count  from (SELECT DISTINCT 'Data Readouts' as key_events_label, coalesce(ipp_short_name, '') as ipp_short_name, project_type, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\n\tFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \n\tINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \n\tWHERE activity_type in ('MA_SUB_DATE_US_COND', 'MA_SUB_DATE_EX_US_COND', 'MA_SUB_DATE_US', 'MA_SUB_DATE_EX_US') \n\tAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\n\tAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, now()))) as a\nWHERE activity_type in ('MA_SUB_DATE_US_COND', 'MA_SUB_DATE_EX_US_COND', 'MA_SUB_DATE_US', 'MA_SUB_DATE_EX_US') \nAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\nAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, now())\n\n\nunion \n\n\nSELECT 'Launches' as key_events_label, a.rec_count, coalesce(ipp_short_name, '') as ipp_short_name, milestone_short_name, description, geographic_area, end_date\nfrom \n(\nSELECT DISTINCT  coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\nFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \nINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \nWHERE activity_type in ('LAU_US', 'LAU_EU', 'LAU_OTHER') \nAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\nAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab)  between now() AND  date_add('month', 3, now())\nunion \nSELECT DISTINCT coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\nFROM edf_prd_cdl_clindev_ppm_publish.ipp_bu_pub_act x   \nINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \nWHERE geographic_area in ('United States', 'European Union', 'Japan', 'China')\nAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, Now())\n)\ncross join\n\t(\n\tSELECT count(*) as rec_count\n\tfrom (\n\tSELECT DISTINCT  coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\n\tFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \n\tINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \n\tWHERE activity_type in ('LAU_US', 'LAU_EU', 'LAU_OTHER') \n\tAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\n\tAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab)  between now() AND  date_add('month', 3, now())\n\tunion \n\tSELECT DISTINCT coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\n\tFROM edf_prd_cdl_clindev_ppm_publish.ipp_bu_pub_act x   \n\tINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category  \n\tWHERE geographic_area in ('United States', 'European Union', 'Japan', 'China')\n\tAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, Now())\n\t)\n\t) as a\n\n\n\nunion \n\nSELECT DISTINCT 'Portals' as key_events_label, a.rec_count, coalesce(ipp_short_name, '') as ipp_short_name, x.milestone_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\nFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \nINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \ncross join (select count() as rec_count  from (SELECT DISTINCT 'Data Readouts' as key_events_label, coalesce(ipp_short_name, '') as ipp_short_name, description, geographic_area, coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) as end_date\n\tFROM edf_prd_cdl_clindev_ppm_publish.ipp_pub_act x   \n\tINNER JOIN edf_prd_cdl_clindev_ppm_publish.milestone_reference y ON x.milestone_category = y.milestone_category \n\tWHERE activity_type in ('PT_PORTAL','FIH_PORTAL','E2L_PORTAL','POC','CTRS_PORTAL','CTF_PORTAL','CTEF_PORTAL','CTFF_PORTAL','CTL_PORTAL') \n\tAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\n\tAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between date_add('day', -1, now()) AND  date_add('month', 3, now()))) as a\nWHERE activity_type in ('PT_PORTAL','FIH_PORTAL','E2L_PORTAL','POC','CTRS_PORTAL','CTF_PORTAL','CTEF_PORTAL','CTFF_PORTAL','CTL_PORTAL')\nAND geographic_area in ('United States', 'European Union', 'Japan', 'China')\nAND coalesce(end_date_pg_approved_baseline, end_date_current_approved_cab) between now() AND  date_add('month', 3, now())\n\nunion \n\nselect distinct 'Competitive Intelligence' as key_events_label, a.rec_count, y.competitor_asset, y.competitor, event_name as description, coalesce(x.country, '') as geographic_area, start_date as end_date\nFROM edf_prd_cdl_clindev_cistrategy_publish.ci_event x,  edf_prd_cdl_clindev_cistrategy_publish.ci_asset y\ncross join (select count() as rec_count from (SELECT DISTINCT 'Competitive Intelligence' as key_events_label, y.competitor_asset, y.competitor, event_name as description, coalesce(x.country, '') as geographic_area, start_date as end_date\n\tFROM edf_prd_cdl_clindev_cistrategy_publish.ci_event x,  edf_prd_cdl_clindev_cistrategy_publish.ci_asset y \n\tWHERE  start_date between now() AND  date_add('month', 3, now()))) as a\nWHERE  start_date  between now() AND  date_add('month', 3, now())\nand country  in ('US', 'EU', 'Japan', 'China')\n\n\n\n)\nORDER BY key_events_label, end_date\n": [
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBEerate-H2H vs Repatha vs alirocumab completion",
		"geographic_area" : "US",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated Biocon\/Viatris EYLEA biosimilar MYL-1701P US filing approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Dupixent Prurigo Nodularis US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Xolair auto-injector US approval",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Estimated launch of Leqvio in Italy",
		"geographic_area" : "EU",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Adagrasib monotherapy US accelerated approval in 2L+ NSCLC",
		"geographic_area" : "US",
		"end_date" : "2022-10-01"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Leqvio",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB16",
		"project_type" : "Samsung Biologics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "cendakimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ODM-208",
		"project_type" : "Merck, Orion",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CSJ117",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TVB009",
		"project_type" : "Teva",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06835375",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lerodalcibep",
		"project_type" : "LIB Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xolair",
		"project_type" : "Genentech \/ Roche, Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "remibrutinib",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ritlecitinib",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LAVA-1207",
		"project_type" : "Lava Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kevzara",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Dupixent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skyrizi",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN4336",
		"project_type" : "Regeneron",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Remicade",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MSC",
		"project_type" : "Hope Biosciences",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI-730357",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RRx 001",
		"project_type" : "EpicentRx",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Stelara",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06700841",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PF 06826647",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Kyntheum",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SCD-044",
		"project_type" : "Sun Pharma",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Roflumilast",
		"project_type" : "Arcutis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima & Keytruda with or without Chemo",
		"project_type" : "Esai, Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orismilast",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NDI-034858",
		"project_type" : "Nimbus Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lebrikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Canakinumab & Keytruda & Chemo",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rimegepant",
		"project_type" : "Biohaven",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "bb21217",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Qulipta",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bemcentinib & Keytruda",
		"project_type" : "BerGenBio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Olumiant",
		"project_type" : "Eli Lilly, Incyte",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Onvansertib",
		"project_type" : "Cardiff Oncology",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ubrelvy",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALD1910",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cibinqo",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Trastuzumab deruxtecan",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "PBCAR269A",
		"project_type" : "Precision BioSciences",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Emgality",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sarclisa",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-TLX591",
		"project_type" : "Telix",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Magrolimab",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Botox",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TAK 079",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rubraca",
		"project_type" : "Clovis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1133",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "amlitelimab",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3537982",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula & Zytiga",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Opdivo",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IRL201805",
		"project_type" : "Immune Regulation",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Keytruda",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T-Oslo Univ.",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS986207",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Otilimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sitravatinib & Opdivo",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "teriparatide",
		"project_type" : "Teva",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-428",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosentyx",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zejula",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Praluent",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PSMA-617",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3462817",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177 Lu DLL3",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vascepa",
		"project_type" : "Amarin",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB585",
		"project_type" : "Teneobio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Taltz",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "177Lu-PNT2002",
		"project_type" : "POINT Bio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Itepekimab",
		"project_type" : "Regeneron, Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX1719",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Mirikizumab",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MRTX9768",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "lirentelimab",
		"project_type" : "Allakos",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "IDE397",
		"project_type" : "Glaxo Smith Kline, IDEAYA Biosciences",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NKTR 358",
		"project_type" : "Eli Lilly, Nektar",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revolade",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JTE 451",
		"project_type" : "Akros",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bezeran",
		"project_type" : "Novartis, Beigene",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "XPOVIO",
		"project_type" : "Karyopharm",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Keytruda & Lynparza",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Orencia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P42",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO605",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "STEAP1 CAR-T",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Piclidenoson",
		"project_type" : "Canfite",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB203",
		"project_type" : "Bioeq, Formycon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Datopotamab deruxtecan",
		"project_type" : "Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB12",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Revlimid",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB17",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Enhertu",
		"project_type" : "AstraZeneca, Daiichi Sankyo",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FYB202",
		"project_type" : "Bioeq, Formycon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecartus",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bmab1200",
		"project_type" : "Biocon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GDC-6036",
		"project_type" : "Genentech \/ Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CTP41",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adagrasib",
		"project_type" : "Mirati",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "depemokimab",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "INBRX105 (ES101)",
		"project_type" : "Episcience, Inhibrx",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ABBV-154",
		"project_type" : "AbbVie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simlukafusp alfa",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Branebrutinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lenvima with or without Keytruda",
		"project_type" : "Esai, Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ORTD-1",
		"project_type" : "Oryn Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BMS 0986012",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "EDP1815",
		"project_type" : "Evelo",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Talzenna & XTANDI",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Siliq",
		"project_type" : "Ortho Dermatologics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-8081",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tapinarof",
		"project_type" : "Dermavant",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nivolumab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Saphnelo",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK0616",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lu AG09222",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tyvyt",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Blenrep",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MYL-1701P",
		"project_type" : "Biocon\/Viatris",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SAR442085",
		"project_type" : "Sanofi",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT04",
		"project_type" : "Alvotech, Stada, Teva",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Teclistamab",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SB15",
		"project_type" : "Samsung",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BI764532",
		"project_type" : "Boehringer Ingelheim",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "REGN5678",
		"project_type" : "Regeneron",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG908",
		"project_type" : "Tango Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3473329",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT-P43",
		"project_type" : "Celltrion",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rabeximod",
		"project_type" : "Cyxone",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "tozorakimab",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pelacarsen",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Fasenra",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Humira",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ligelizumab",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "VIB4920",
		"project_type" : "Viela Bio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nucala",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Duobrii",
		"project_type" : "Ortho Dermatologics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SLN360",
		"project_type" : "Silence Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tremfya",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Forteo",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Skilarence",
		"project_type" : "Almirall",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JNJ-80038114",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bimekizumab",
		"project_type" : "UCB",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BAT2206",
		"project_type" : "Bio-Thera, Hikma",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zeposia",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "SOK583A1",
		"project_type" : "Sandoz",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Deucravacitinib",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab",
		"project_type" : "Genentech \/ Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Adbry",
		"project_type" : "LEO Pharma",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zepzelca",
		"project_type" : "Jazz, PharmaMar",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Entyvio",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Iberdomide",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ajovy",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CT103A",
		"project_type" : "IASO Biotherapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Benlysta",
		"project_type" : "Glaxo Smith Kline",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Elranatamab",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3451838",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC93269",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nurtec ODT",
		"project_type" : "Biohaven",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Jyseleca",
		"project_type" : "Galapagos, Gilead",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO 715",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Sonelokinab",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Abecma",
		"project_type" : "Bristol Myers Squibb, Bluebird Bio",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ilumya",
		"project_type" : "Sun Pharma",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cilta Cel",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "ALLO-605",
		"project_type" : "Allogene",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Ninlaro",
		"project_type" : "Takeda",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Pomalyst",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "MK1084",
		"project_type" : "Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Relatlimab",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Liposomal Irinotecan",
		"project_type" : "Ipsen",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Tiragolumab",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tiragolumab + Atezo + EP",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6291",
		"project_type" : "Revolution Medicines",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tymlos",
		"project_type" : "Radius",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cosela",
		"project_type" : "G1 Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Promacta",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Nubeqa",
		"project_type" : "Bayer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC-1",
		"project_type" : "Academic",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "DMB-3115",
		"project_type" : "Dong-A, Intas",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNG462",
		"project_type" : "Tango",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HBM7022",
		"project_type" : "AstraZeneca",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JANX007",
		"project_type" : "Janux Therapeutics",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "NN6435",
		"project_type" : "Novo Nordisk",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Yescarta",
		"project_type" : "Gilead",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "RMC6236",
		"project_type" : "Revolution Medicines",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "APG 1252",
		"project_type" : "Ascentage",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CB307",
		"project_type" : "Crescendo",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "olokizumab",
		"project_type" : "R Pharm",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "GP2411",
		"project_type" : "Novartis, Sandoz",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AZD8233",
		"project_type" : "AstraZeneca, Ionis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "AVT06",
		"project_type" : "Alvotech, Teva",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Lynparza & Zytiga",
		"project_type" : "AstraZeneca, Merck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN424",
		"project_type" : "Harpoon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CCW702",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN328",
		"project_type" : "Harpoon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq & Cabometyx",
		"project_type" : "Exelixis, Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JDQ443",
		"project_type" : "Novartis",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Tecentriq",
		"project_type" : "Roche",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC92480",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "TNB383B",
		"project_type" : "Abbvie, TNB",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "CC99712",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "BHV3100",
		"project_type" : "Biohaven, Sosei Heptares",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Zavegepant",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Vyepti",
		"project_type" : "Lundbeck",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "litifilimab",
		"project_type" : "Biogen",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "etrasimod",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Simponi",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Xeljanz",
		"project_type" : "Pfizer",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Bempedoic acid",
		"project_type" : "Esperion",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "LY3819469",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "FB704A",
		"project_type" : "Fountain\/ Oneness",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Cimzia",
		"project_type" : "UCB",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Rinvoq",
		"project_type" : "Abbvie",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Netakimab",
		"project_type" : "Biocad",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Reyvow",
		"project_type" : "Eli Lilly",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "Darzalex",
		"project_type" : "Johnson & Johnson",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "HPN217",
		"project_type" : "Abbvie, Harpoon",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Competitive Intelligence",
		"rec_count" : 5328,
		"ipp_short_name" : "JCARH125",
		"project_type" : "Bristol Myers Squibb",
		"description" : "Lerodalcibep Ph3 LIBerate-CVD",
		"geographic_area" : "US",
		"end_date" : "2022-10-31"
	},
	{
		"key_events_label" : "Filings",
		"rec_count" : 3,
		"ipp_short_name" : "Tezepelumab Sev Asthma",
		"project_type" : "Full Filing",
		"description" : "Tezepelumab Severe Asthma",
		"geographic_area" : "European Union",
		"end_date" : "2022-08-31"
	},
	{
		"key_events_label" : "Filings",
		"rec_count" : 3,
		"ipp_short_name" : "Nplate 1L AA",
		"project_type" : "Full Filing",
		"description" : "Nplate 1L Aplastic Anemia",
		"geographic_area" : "Japan",
		"end_date" : "2022-09-22"
	},
	{
		"key_events_label" : "Filings",
		"rec_count" : 3,
		"ipp_short_name" : "Otezla Genital PsO",
		"project_type" : "Full Filing",
		"description" : "Otezla Genital Psoriasis",
		"geographic_area" : "United States",
		"end_date" : "2022-10-12"
	},
	{
		"key_events_label" : "Launches",
		"rec_count" : 5,
		"ipp_short_name" : "AMG 397 MM",
		"project_type" : "Launch",
		"description" : "AMG 397 MM, MCL1 p.o.",
		"geographic_area" : "United States",
		"end_date" : "2022-09-09"
	},
	{
		"key_events_label" : "Launches",
		"rec_count" : 5,
		"ipp_short_name" : "Otezla PsO (mod-to-sev)",
		"project_type" : "Launch",
		"description" : "Otezla Psoriasis PSO (moderate to severe)",
		"geographic_area" : "China",
		"end_date" : "2022-09-15"
	},
	{
		"key_events_label" : "Launches",
		"rec_count" : 5,
		"ipp_short_name" : "AMGEVITA",
		"project_type" : "Full Filing",
		"description" : "AMGEVITA",
		"geographic_area" : "United States",
		"end_date" : "2022-09-30"
	},
	{
		"key_events_label" : "Launches",
		"rec_count" : 5,
		"ipp_short_name" : "AMG 420 MM",
		"project_type" : "Launch",
		"description" : "AMG 420 MM, BCMA BiTE",
		"geographic_area" : "European Union",
		"end_date" : "2022-11-07"
	},
	{
		"key_events_label" : "Launches",
		"rec_count" : 5,
		"ipp_short_name" : "Omecamtiv Heart Failure",
		"project_type" : "Launch",
		"description" : "Omecamtiv Mecarbil",
		"geographic_area" : "China",
		"end_date" : "2022-11-09"
	}
]}
